THERANOSTICS 润色咨询

Theranostics

出版年份：2011 年文章数：3138 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：7.7% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2021-06-10 张晓梅-Xiaomei Zhang

    大家吵来吵去没意义，本质是看你什么目的
    如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了
    如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的
    如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊
    此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人

    54

    展开54条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2021-07-02 susu2019

    偏重的研究方向： 肿瘤
    经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。

    49

    展开49条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2021-01-15 张晓梅-Xiaomei Zhang

    国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell

    28

    展开28条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2021-01-03 1e0cf3e5m18(暂无匿称)

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投

    26

    展开26条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-04-26 ms7000000635207998

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤
    经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。

    20

    展开20条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2020-12-04 Mr.Never Die

    口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两

    16

    展开16条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2021-03-01 张晓梅-Xiaomei Zhang

    有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了

    14

    展开14条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2020-09-20 lmtjmu

    为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态

    12

    展开12条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2020-09-28 425503904

    审稿速度:1.0
    经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲

    12

    展开12条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=972412, encodeId=9bec9e24124d, content=大家吵来吵去没意义，本质是看你什么目的<br>如果是为了升职称之类的，发这个是超值的。7-9分的期刊这个是最容易投的那一类。当然有很多发过的都说难投，这个我们都理解，自己辛苦做的工作投到哪都是有价值的，要说难投建议先试试cell reports和cancer research就知道什么是难了<br>如果是为了申国自然基金，不建议发这个，评委看不起这期刊的，简历上写这个和写个plos one效果是一样的<br>如果是为了出国也不能发这个，在国外这就是个野鸡期刊，还不如oncotarget，有些欧美大牛还会发oncotarget和BBRC这种期刊<br>此外这期刊在一些单位被预警了，社会评价体系就是这样的，你说好我说好有什么用呢，我们都是不掌权的人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=514, replyNumber=54, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Thu Jun 10 09:48:00 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978965, encodeId=aa9b9e8965ca, content=偏重的研究方向： 肿瘤 <br>经验分享：国产大把的期刊发大量letter操作分数不去吐槽，非要来吐槽这个期刊。你们看不上就别发啊，尤其是那些预警的学校，自己把期刊名声搞坏了，还要来吐槽。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=400, replyNumber=49, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Fri Jul 02 12:00:28 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916842, encodeId=f8e791684284, content=国内主办。本来挺好的，后来就开始灌水了，然后就不行了。好文章尽量别投，可以先试试国内办的protein cell, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=294, replyNumber=28, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Jan 15 10:49:39 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913304, encodeId=4e2991330457, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：高分低能水刊，水刊的一种版本，中国占比超过九成，外国人不屑投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=749, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6be81931781, createdName=1e0cf3e5m18(暂无匿称), createdTime=Sun Jan 03 14:39:24 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904942, encodeId=162390494233, content=口碑差为啥这么差 你们心里没点b数吗？，无非是想投八分以上期刊 其他的够不上就只能往这投了呗，真觉得自己的研究那么有价值吗？做人呐，最可悲的莫过于看不清自己几斤几两, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKlT8dqnB7dRUwHjSjzxzL0qta9ib7ZLaLnNhoRG8YDiaKp8zia3TrSBWt1nMZIZUsovyePuKtLCFTOQ/132, createdBy=7b782000120, createdName=Mr.Never Die, createdTime=Fri Dec 04 17:59:40 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944490, encodeId=af4994449064, content=有好文章尽量先往经典期刊上投，然后再往国内靠谱的期刊，例如中科院办的那几个，最后再投这种莫名其妙蹭蹭往上涨的。这种期刊风险太大了，说不准就变成水刊了，还是有很多文章不错的，发在这上面亏了。没办法呀，国内评各种基金奖励，就看你发哪个期刊了，不看你的内容。 不管你说是不是水刊，现在很多评基金的评委已经认为这是水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Mon Mar 01 16:53:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886900, encodeId=db1488690056, content=为什么我的投出去了 还显示文章 推荐审稿人这些可以替换啊 完全看不懂这个杂志的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d2f2374635, createdName=lmtjmu, createdTime=Sun Sep 20 16:45:31 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888895, encodeId=e8ce88889506, content=审稿速度:1.0<br>经验分享：为什么这个杂志的囗碑这么差阿？刚接收了一篇，希望IF能稳住。好不容易发了个高分的，都有点不好意思跟别人讲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/4b4bb41d91c344638c4646860774486f/8e4b49c830ff47b09271b2baf9987dd2.jpg, createdBy=19a93002970, createdName=425503904, createdTime=Mon Sep 28 13:36:59 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=305, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-09-11 1811e984f8m

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：分子生物
    经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。

    10

    展开10条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分